CHRS vs GS · rev $26.6M vs P/E 20, rev $37.56B
Coherus BioSciences Inc (CHRS) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Coherus BioSciences Inc (CHRS) is a biotechnology company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported CHRS revenue for 2026-06-30 was $26.6M. Net income was -$59.0M. CHRS currently screens at market cap $223.7M.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
CHRS currently screens at market cap $223.7M. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the CHRS and GS stock pages for the full models.
Not investment advice.